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Abstract
Between 10 and 25% of individuals with non-alcoholic fatty liver disease (NAFLD) develop hepatic fibrosis leading to
cirrhosis and hepatocellular carcinoma (HCC). To investigate the molecular basis of disease progression, we performed a
genome-wide analysis of copy number variation (CNV) in a total of 49 patients with NAFLD [10 simple steatosis and 39 non-
alcoholic steatohepatitis (NASH)] and 49 matched controls using high-density comparative genomic hybridization (CGH)
microarrays. A total of 11 CNVs were found to be unique to individuals with simple steatosis, whilst 22 were common
between simple steatosis and NASH, and 224 were unique to NASH. We postulated that these CNVs could be involved in the
pathogenesis of NAFLD progression. After stringent filtering, we identified four rare and/or novel CNVs that may influence
the pathogenesis of NASH. Two of these CNVs, located at 13q12.11 and 12q13.2 respectively, harbour the exportin 4 (XPO4)
and phosphodiesterase 1B (PDE1B) genes which are already known to be involved in the etiology of liver cirrhosis and HCC.
Cross-comparison of the genes located at these four CNV loci with genes already known to be associated with NAFLD
yielded a set of genes associated with shared biological processes including cell death, the key process involved in ‘second
hit’ hepatic injury. To our knowledge, this pilot study is the first to provide CNV information of potential relevance to the
NAFLD spectrum. These data could prove invaluable in predicting patients at risk of developing NAFLD and more
importantly, those who will subsequently progress to NASH.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) has emerged as a
silent epidemic, with its worldwide prevalence continuing to
increase with the growing incidence of obesity [1]. NAFLD
comprises a spectrum of diseases ranging from simple steatosis,
which is essentially benign fatty infiltration of the liver, to its
inflammatory counterpart non-alcoholic steatohepatitis (NASH)
[2]. The pathogenesis of NAFLD is based on the ‘‘two hit
hypothesis’’ [3]. The ‘‘first hit’’ is the development of steatosis and
involves the accumulation of triglycerides in the liver due to insulin
resistance. Insulin resistance prepares the hepatocytes for the
second insult. The ‘‘second hit’’ is often due to adipocytokines and
oxidative stress, which further damage the liver thereby promoting
progression to steatohepatitis and fibrosis. A significant proportion
of individuals with NAFLD develop hepatic fibrosis, a key feature
of the condition which is associated with progression of the disease
to cirrhosis and its related complications, including hepatic failure
and hepatocellular carcinoma [4]. The fibrotic progression of
NAFLD is identified histologically by the presence of NASH. A
high prevalence of NASH is found among those with insulin
resistance-related comorbidities such as obesity and type 2 diabetes
[5]. The mortality rate among NASH patients has been found to
be much higher than for patients with simple fatty liver (simple
steatosis) [6].
In addition to environmental factors such as high calorific food
intake and a sedentary lifestyle, there is mounting evidence of a
genetic component to the complex etiology of NAFLD [7]. This is
reflected by marked differences in the prevalence of NAFLD
across diverse populations [8–9]. The high heritability of NAFLD
was evident in a familial aggregation study, with estimates of 59%
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in siblings and 78% in parents with NAFLD [10]. Until recently,
genome-wide association studies (GWAS) and the candidate gene
approach have both utilised single nucleotide polymorphisms
(SNPs) to explain the genetic component of NAFLD [7,11–12].
The wide distribution of copy number variants (CNVs) in the
human genome has underscored the importance of CNVs in
relation to genetic diversity, phenotypic variability and disease
susceptibility [13–14]. It has been estimated that approximately
12% of the human genome is copy number variable [15] with
over 1000 genes having been mapped within or close to regions
that are affected by structural variation [16]. A global increase
in CNV burden has also been observed in polygenic traits such
as schizophrenia [17], autism [18] and attention deficit
hyperactivity disorder [19]. Given these findings, the sheer
scale of CNVs means that they are likely to make a significant
contribution to the ‘missing heritability’ of some of these
conditions [20]. However, despite some success in identifying
CNVs responsible for metabolic phenotypes including obesity
and diabetes mellitus [21–22], there are as yet no data available
to suggest whether or not CNVs might be involved in the
etiology of the NAFLD spectrum.
Here, we describe a pilot study designed to detect rare or novel
CNVs associated with NAFLD and/or NASH. Predicting NASH
non-invasively is very important since this condition is potentially
progressive and liver biopsy is currently the gold standard for the
diagnosis of NASH. We interrogated the CNVs associated with
NASH and ascertained the biological processes associated with
those genes covered by the CNVs in order to assess their possible
role in the progression of the disease. To this end, we used a high-
resolution Agilent aCGH platform to perform genome-wide copy
number analysis in patients with both simple steatosis and NASH,
which are representative of the clinical spectrum of NAFLD.
Materials and Methods
Ethics Statement
The study protocol was approved by the Medical Ethics
Committee of UMMC and all subjects provided their written
informed consent to participate.
Subjects
Genome-wide copy number profiling was performed using
array comparative genomic hybridization (aCGH) on a total of
49 NAFLD patients (39 with NASH and 10 with simple
steatosis) and 49 fatty liver-free controls that were matched both
for age and gender. All subjects were, as far as could ascertain,
genetically unrelated to each other. All NAFLD patients were
consecutively recruited from the University of Malaya Medical
Centre (UMMC). NAFLD was confirmed through liver
histology and evaluated according to the NASH Clinical
Research Network criteria [23–24]. All liver biopsy specimens
were on average 1.5 cm long and contained at least six portal
tracts. Subjects were excluded if they met any of the following
criteria: (i) alcohol consumption .10g/day [25]; (ii) hepatitis B
or C infection; (iii) autoimmune hepatitis; (iv) exposure to drugs
known to cause steatosis or (v) Wilson’s disease. The controls
were genetically unrelated healthy subjects with a body mass
index (BMI) ,25 kg/m2, a fasting plasma glucose of ,110 mg/
dL, a normal lipid profile and normal liver enzymes. NAFLD
was actively excluded in the controls by ultrasonography
according to the absence of the following criteria: (i) slight
diffuse increase in bright homogeneous echoes in the liver
parenchyma with normal visualization of the diaphragm and
portal and hepatic vein borders, and normal hepatorenal
echogenicity contrast; (ii) diffuse increase in bright echoes in
the liver parenchyma with slightly impaired visualization of the
Table 1. Histopathological data in patients with NAFLD.
NASH (n=39) Simple steatosis (n =10)
Steatosis grade
1 11 9
2 20 1
3 8 0
Inflammatory activity
0 1 3
1 19 7
2 19 0
3 0 0
Ballooning
0 0 10
1 21 0
2 18 0
Fibrosis stage
0 0 10
1 12 0
2 19 0
3 6 0
4 2 0
NASH, non-alcoholic steatohepatitis.
doi:10.1371/journal.pone.0095604.t001
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peripheral portal and hepatic vein borders; (iii) marked increase
in bright echoes at a shallow depth with deep attenuation,
impaired visualization of the diaphragm and marked vascular
blurring [26]. Subsequent magnetic resonance imaging (MRI) to
further confirm the fatty liver free status was performed.
Array CGH
Array-CGH was performed according to the protocol
established by the manufacturer (Oxford Gene Technology,
Begbroke, UK). It was carried out using the SurePrint G3
Human CGH 26400 K array (Agilent Technologies, Santa
Clare, CA, USA) for genome-wide identification of putative
disease-associated CNVs. Each oligonucleotide-based microarray
slide contained 410,739 probes that enabled the profiling of
molecular genomic imbalances with a mean resolution of
5.3 kb. Probes on the array were 60-mers and covered both
coding and non-coding regions of the human genome. A total
of 1.0 mg genomic DNA from patients and controls was labeled
with Cy3 and Cy5 dyes respectively using the CytoSure
Genomic DNA labeling kit (Oxford Gene Technology). Probes
were then purified using Microcon Centrifugation Filters,
Ultracel YM-30 (Millipore, Billerica, MA, USA) and mixed
thoroughly. This was followed by denaturation and pre-
annealing with 50 mg human Cot-1 DNA (Invitrogen, Califor-
nia). Hybridization of the mixture to the array slide was
executed at a constant rotation at 65uC for 40 hours. The slide
was then washed with Agilent wash buffers 1 and 2, and
scanned immediately using an Agilent Microarray scanner
(Agilent Technologies, Santa Clara, CA, USA). Data were
extracted from scanned images using Feature Extraction
Software, version 10.7.3.1 (Agilent Technologies, USA). The
raw data obtained thereafter were uploaded into the CytoSure
Interpret software version 4.2.5 (Oxford Gene Technology),
normalized and converted into.cgh files. Data normalization
software was used to improve inconsistencies in dye incorpora-
tion. The data were segmented using a modified Circular
Binary Segmentation (CBS) algorithm [27]. Genomic aberra-
tions were identified by applying log2 intensity ratios of sample
to reference (Cy3/Cy5: log2-ratios above 0.3 for duplications
and below 20.6 for deletions). Chromosomal aberrations were
reported in accordance with the human genome sequence
assembly Build 37, hg 19 (http://www.ncbi.nlm.nih.gov). The
microarray data have been deposited in the Gene Expression
Omnibus (GEO) database (accession number 55645).
CNV Calling and Functional Enrichment Analysis
CNVs were called for the segments with at least 5
consecutive probes. Rare CNVs were defined as those which
overlapped by ,50% with reported CNVs from the Database
of Genomic Variants (DGV; http://dgv.tcag.ca/dgv/app/
home). CNVs were deemed to be novel if they did not appear
in the DGV database. Gene content within the identified CNVs
was retrieved from the Homo sapiens (GRCh27) assembly using
the Biomart-Ensembl (http://www.ensembl.org). By default, the
lists contained both gene and non-gene entities; the latter were
removed through a process of cross-checking and verification of
gene symbols using the HUGO Gene Nomenclature Committee
(HGNC) database (http://www.genenames.org/). To investigate
the functional impact of rare and/or novel CNVs, the Database
for Annotation, Visualization and Integrated Discovery (DA-
VID; http://david.abcc.ncifcrf.gov/) was utilised to assess the
Gene Ontology (GO; http://www.geneontology.org/) and
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
(http://www.genome.jp/kegg/) annotations between the genes
encompassing the rare and/or novel CNVs and the genes
associated with NAFLD. The list of genes associated with
NAFLD was identified using the MalaCards database (http://
www.malacards.org/) – an integrated searchable database of
human disease states and their annotations, in association with
the GeneCards relational database. Initially, a total of 200 genes
associated with NAFLD were identified. Since the gene-disease
association was based on a text mining algorithm, a manual
verification of the biological processes associated with each of
the 200 genes was performed. Only genes that had previously
been described as being associated with NAFLD by either
expression studies, genotyping or protein array work were
selected, thereby lowering the number of genes implicated in
NAFLD to 70 (see Table S1 for the complete list of genes).
Figure 1. Size range distribution of the CNVs. The CNVs ranged in size from 5.77 kb to 8.15 Mb with a mean size of 194.94 kb and a median size
of 38.33 kb.
doi:10.1371/journal.pone.0095604.g001
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Quantitative PCR Validation of CNV Calls
A duplex TaqMan real-time quantitative polymerase chain
reaction (qPCR) was performed to validate the CNV regions using
a Step One Plus (Applied Biosystems) on three of the samples from
two selected regions (11q11: Assay Hs02799097_cn, and
13q12.11: Assay Hs03857719_cn). Each reaction (20 mL) con-
tained 10 mL master mix, 1 mL TaqMan Copy Number Assay,
1 mL TaqMan Copy Number Reference Assay, 4 mL nuclease free
water, and 4 mL 5 ng/mL genomic DNA, and was run in
quadruplicate. The PCR cycling conditions consisted of 1 PCR
cycle at 95uC for 10 min, followed by 40 cycles at 95uC for 15 sec
and 60uC for 1 min.
Results
In the aCGH method adopted, DNA samples pooled from
multiple subjects (patients and controls) were cross-compared so as
to remove/normalise any common copy number changes in the
normal control sample. Since the principle of aCGH is to compare
the DNA copy number from patient samples against those of
normal controls, CNV calls were designed to be patient-specific.
Subjects and Identification of CNVs in the NASH Genome
All DNA samples passed quality control (QC) after a rigorous
sample preparation process and a QC check during sample
processing. Sets of 39 NASH samples and 39 matched controls
were run in parallel on an array CGH platform that allowed
the ratio of DNA copy number between a test (patient) and a
reference (control) to be simultaneously assessed. From a total of
39 samples, 51.3% (n=20) were females, 48.7% (n= 19) were
males; the mean age of the 39 subjects was 50.4 years. The
histopathological data are presented in Table 1. Seven percent
of CNV calls were attributable to the sex chromosomes (with a
frequency of at least 10%), but we opted to exclude these
chromosomes from further analysis owing to the evolutionary
biases due to small imbalances of the sex chromosomes [28].
Analysis of copy number variants, on the basis of log ratio and
probe incidence filtering, yielded a total of 267 autosomal
CNVs (the ratio of the fluorescence intensities between the
patients and controls is a measure of the relative DNA copy
number), amounting to an average of 6.84 autosomal CNVs per
individual. The 267 CNVs detected spanned between 5.77 kb
and 8.15 Mb in size, with a mean size of 194.94 kb and a
median size of 38.33 kb, covering a total of 52.05 Mb or 1.63%
of the genome (Fig. 1). Most chromosomal arms harboured both
copy number gains and losses, but copy number gains were
more commonly observed than losses (estimated ratio of 1.7:1).
However, only 55 CNVs (20.6%) out of the 267 CNVs detected
had a frequency of .10%.
Molecular genomic profiling identified 14q11.2 as the most
frequently amplified region, which occurred in 53.8% of the
NASH samples and contained a clutch of olfactory receptor (OR)
family genes (Table 2; see Table S2 for the full list of OR genes).
The most frequently deleted genomic region in the NASH
samples, 12p13.2, is enriched in taste receptor (TASR) family
genes (see Table S2 for the full list of TASR genes), and exhibited
similar frequencies of losses and gains (38.5%) suggesting a
generally unstable region. Several other frequently deleted regions
were also observed including one at 16q12.2 harbouring the
carboxylesterase 1 (CES1) gene and one at 14q24.3 spanning the
acyl-CoA thioesterase 1 (ACOT1) gene; importantly, both genes
are known to promote hepatic steatosis via the action of regulation
of hepatic lipid metabolism [29–30]. There were nine CNVs
present in at least 33% of the samples whilst only one was present
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in at least half of the samples. Six CNVs occurred with a frequency
of at least 10% in samples which contained copy number
duplications in the chromosomal regions 16p12.2 (27.5%),
12q24.33 (12.8%), 22q13.2 (12.8%), 12q13.2 (10.3%), 2q37.1
(10.3%) and 21p11.2-p11.1 (10.3%), implying that these regions
could be involved in the development of NASH. Overall, nearly
50% of genomic regions were reported only as copy number gains;
however, only 6 of these regions were present at a frequency of
more than 10%. By contrast, about 18% of the genomic regions
presented only as losses; however, none had a frequency greater
than 10%.
Integrative Analysis of CNVs and Functional Enrichment
to Identify Candidate Genes for Involvement in NASH
To identify unique CNVs in NASH patients that could be
involved in the pathogenesis of this condition, we performed a
cross-comparison with known CNVs from the DGV database.
Conservative assessment of the overlap between reported CNVs
from the DGV database with the CNVs identified in this study
revealed four rare and/or novel CNVs (DGV coverage ,50%)
that were present in at least 10% of the NASH samples
(Table 3). Two of these CNVs were classed as rare (DGV
coverage ,50%: 12q24.33 and 13q12.11), whereas the other
two were novel (DGV coverage 0%: 21p11.1–11.2 and
12q13.2). A Chi-square test confirmed the significance of the
association of these CNVs with NASH (P,0.05) as compared to
simple steatosis. To further assess the likelihood of the
involvement of these CNVs in NASH, the genes located within
these regions were identified and their involvement in those
biological processes shared with known NAFLD genes assessed.
First, we profiled the genes within the chromosomal regions that
are bounded by the four rare and/or novel CNVs, where genes
such as exportin 4 (XPO4) and phosphodiesterase 1B (PDE1B)
are located. A list of genes known to be associated with NAFLD
was then obtained (see Table S1). Subsequently, we performed
GO enrichment and KEGG pathway analysis using the DAVID
gene annotation tool for the two sets of genes (genes within the
four unique regions and known genes associated with NAFLD).
We observed a number of shared biological processes (Table 4)
between the two sets of genes including those that could be
linked to NAFLD progression such as glucose metabolism, cell
surface receptor-linked signal transduction and cell death [3].
Identification of CNVs in the Simple Steatosis Genome
Given the greater number of NASH samples (,80%) and the
progressive nature of NASH (about one third of NASH patients
tend to develop cirrhosis over a 5–10 year period; by contrast,
simple steatosis patients tend to be clinically stable over time) [31]
in the disease spectrum, the main focus of this study was placed on
NASH. However, we were also interested in understanding the
progression of simple steatosis to NASH. Unfortunately, we were
only able to obtain DNA samples from 10 simple steatosis patients
and 10 fatty-liver free controls. Seven of the samples were male
and the mean age (all samples) was 47.9. The histopathological
data are shown in Table 1. A total of 56 CNVs (simple steatosis
patient-specific) were identified, including three (5.4%) which were
located on one of the sex chromosomes. All CNVs were present
with a frequency of at least 10%. Fifty-three autosomal CNVs
were selected for further analysis. Of these, 11 were unique to
simple steatosis whereas 42 were found to be shared with NASH.
The former 11 CNVs could conceivably play a role in the
development of hepatic steatosis, whereas the latter 42 CNVs
could be involved in progression to steatohepatitis. Intriguingly,
the four rare and/or novel CNVs identified earlier in NASH
patients were not found in simple steatosis patients, and remain
unique to NASH.
The top scoring regions in terms of copy number gains and
losses in simple steatosis are listed in Table 5. The most
commonly amplified region, 12p13.31 (50%), was also among
the most highly amplified regions observed in NASH patients. A
CNV at the 10q11.22 locus that occurred in 40% of the simple
steatosis samples contains the neuropeptide Y receptor 4
(NPYR4) gene, which is known to be important in obesity
through the regulation of appetite and energy metabolism [32].
Three CNVs (located at 4q13.2, 15q11.2 and 11q11) shared the
most deleted region at a frequency of 40%, in which two of the
CNVs (4q13.2 and 11q11) were also among the most highly
deleted regions observed in NASH. These CNVs were enriched
Table 4. Enriched GO terms associated with NASH.
Category Term Count
Involved genes/
total genes (%) P-Value*
GO_CC GO:0005576,extracellular region 34 44.16 1.2E-10
GO_BP GO:0006006,glucose metabolic process 6 7.79 2.0E-04
GO_BP GO:0019318,hexose metabolic process 6 7.79 6.8E-04
GO_BP GO:0005996,monosaccharide
metabolic process
6 7.79 1.4E-03
GO_BP GO:0015980,energy derivation
by oxidation of organic compounds
4 5.19 8.3E-03
GO_BP GO:0007186,G-protein coupled
receptor protein signaling pathway
12 15.58 2.0E-02
GO_BP GO:0007166,cell surface receptor
linked signal transduction
16 20.78 4.6E-02
GO_BP GO:0006091,generation of
precursor metabolites and energy
5 6.49 3.0E-02
GO_BP GO:0008219,cell death 8 10.39 4.5E-02
GO_BP, Gene Ontology biological process; GO_CC, Gene Ontology cellular component.
*Modified Fisher’s Exact test, P-Value #0.05.
doi:10.1371/journal.pone.0095604.t004
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for OR genes (11q11) and immunoglobulin heavy chain (IGH)
(15q11.2) family genes (Table 4; see Table S2 for the full list of
OR and IGH genes). However, all CNVs identified in the simple
steatosis patients were common (DGV coverage 100%).
qPCR Validation
We validated three samples (each is patient-control matched
pair) for each CNV region identified. We selected two CNV
regions that represented different statuses of copy number change
(the CNV at 13q12.11 was a copy number gain and was rare,
11q11 was a copy number loss). All CNVs were confirmed
through qPCR validation. Amplifications and deletions of the
genomic regions were defined on the basis of differences between
patient’s copy number and the wild-type copy number (i.e. a copy
number around 2). Fig. 2 illustrates the qPCR results of the
validated CNVs.
Discussion
Studies on CNVs are becoming increasingly important in
studies of inherited disease, with growing evidence attesting to the
substantial impact that they can have on human phenotypic
variability and genetic susceptibility. Here, we present a pilot
analysis of CNVs in a series of NAFLD patients. We identified four
CNVs that are either rare or novel to NASH patients in our study
that could potentially contribute to clinical outcome.
In patients with NASH, the most frequently amplified region
was 14q11.2, which is enriched in OR family genes, while an
abundance of TASR family genes were found at 12p13.2, the
most frequently deleted region. Although the OR and TASR
families play roles in the olfactory and gustatory systems
respectively, a search of the database of Expressed Sequence
Tags, NCBI dbEST, revealed OR and TASR gene expression in
many tissues and organs, including the liver. Impairment of
olfactory and gustatory function has been reported in chronic
liver disease including cirrhosis; chemosensory function however
improved after liver transplantation [33]. In the early 2000s, a
comprehensive database of the human olfactory subgenome was
completed using a highly automated data mining system [34].
Glusman et al. (2001) reported the presence of 906 potential
coding regions for OR genes that cover almost all human
chromosomes with the exception of chromosomes 20 and Y, in
which 2/3 of the regions have not been reported. Subsequently,
new databases termed respectively the Olfactory Receptor
Microarray Database (ORMD) which includes microarray gene
expression data from the ORs [35], and the Database of
Chemosensory Receptor Gene Families (CRDB), were devel-
oped [36]. The size of these databases highlights the importance
of OR and TASR gene families not only in the olfactory and
gustatory systems, but also in tissues and organs throughout the
body.
A deletion CNV was noted at the 16q12.2 locus; it includes
the CES1 gene, which is primarily important in the metabolism
of fatty acids and cholesterol [37]. Expression of CES1 has been
found to be higher in human NAFLD hepatic tissue as
compared to non-NAFLD [38]. A role for CES1 in lipolysis
was evidenced by a positive correlation between CES1
expression and triglyceride lipase activity as well as with
adiposity [30]. On the other hand, CES1 knockout mice are
characterized by a gain in weight, hepatic steatosis and
hyperinsulinemia, thereby supporting a role for CES1 in the
regulation of fatty acids [37]. Interestingly, the 16q12.2 locus is
known to harbour genetic variants (SNPs) associated with BMI
[39]. Although CES1 has been implicated in hepatic steatosis
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[37], a recent study has shown that CES1 may have potential
as a biomarker to distinguish hepatocellular carcinoma (HCC)
from cirrhosis [40]. Also notable among the highly deleted
regions in NASH patients was a copy number loss at the
14q24.3 locus, where the acyl-CoA thioesterase 1 (ACOT1) gene
resides. Acyl-CoA thioesterase 1 promotes the cellular balance
between free fatty acids and acyl-CoAs to maintain cellular
processes including lipid metabolism [29]. Compared to other
ACOT subfamily genes, ACOT1 is unique in that it is highly
expressed only in association with a high fat diet but not in
association with a normal diet [41].
Although determining the CNV frequencies and their gene
content are important, most of the CNVs detected here are
considered to be common (DGV coverage 100%) and hence
may have little or no impact on the pathogenesis of NASH.
The definition of ‘common’ here is however debateable given
that reported CNVs from the DGV are (i) from non-NAFLD
studies and (ii) unlikely to be from the Malay population.
Figure 2. qPCR validation performed on selected genomic regions. (A) Results for the region 11q11. (B) Results for the region 13q12.11. A
copy number of around 2 was deemed to be indicative of wild-type status (i.e. no CNV), a copy number of 1 was indicative of one copy lost, whereas
a copy number of 3 or above was held to indicate copy number gain(s). The error bars represent the standard error among four replicates.
doi:10.1371/journal.pone.0095604.g002
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Caution should therefore be exercised when offering functional
interpretation of these CNVs until more comprehensive studies
on larger numbers of patients are conducted. To achieve our
main goal in this pilot study, which was to identify candidate
CNV loci that could play a role in the etiology of NASH, we
filtered out common CNVs and identified four CNVs (DGV
coverage ,50%) that have the potential to be involved in the
pathogenesis of NASH; two of these are rare (12q24.33 and
13q12.11) whilst two are novel (12q13.2 and 21p11.1–11.2). We
were able to establish the potential significance of these loci by
performing a Chi-square test against other loci and validating
the findings by qPCR; in this way, we were able to confirm
that, despite the relatively small sample size, our analysis has
the potential to yield biologically meaningful and reproducible
results. We postulate that these CNVs could provide new
insights into the biology of NASH. Of particular note was an
aberration at the 13q12.11 locus that could serve as a potential
copy number biomarker for NASH. This region contains the
tumor suppressor gene exportin 4 (XPO4), the inactivation of
which promotes HCC in mice [42]. On the other hand,
increased expression of XPO4 in human HCC is associated with
better prognosis and a better survival rate [43–44]. The
phosphodiesterase 1B, calmodulin-dependent (PDE1B) gene
spanning the 12q13.2 region is important in many signal
transduction pathways, and has been found to be downregulat-
ed in cirrhotic liver [45]. The 12q13.2 locus was identified as a
clear-cut amplification (no deletion event), thereby supporting its
candidacy as a potential risk marker CNV associated with the
disease. However, there are a limited number of published
reports on XPO4 and PDE1B and their putative role in liver
disease. Thus, additional comprehensive studies focussed on
these two genes will be necessary to confirm or refute this
finding.
To assess the plausibility of our results, it was important to
verify the functional role of these CNVs (rare/novel) and their
potential impact on NASH. In order to explore the possible
association between these CNVs and NASH, we extended our
analysis to GO functional enrichment and KEGG pathway
analysis for genes residing at these CNV loci and known
NAFLD genes. The results yielded several shared biological
processes between the two sets of genes. Of primary importance
are glucose metabolism and cell surface receptor-linked signal
transduction and cell death, all of which have been shown to be
important in the pathogenesis of NASH [4]. However, no
related KEGG pathway was observed.
As for simple steatosis, the most frequently amplified region
(12p13.31) also happened to be among the most highly
amplified regions in NASH. The 10q11.22 region, which
harbours a CNV that occurred in 40% of the simple steatosis
samples, contains the NPYR4 gene. This gene is involved in the
regulation of appetite and energy metabolism [32]. The
pancreatic peptide, a high affinity ligand for the neuropeptide
Y receptor 4 (Y4), has been suggested to have anti-obesity
potential [46–47]. Long term antagonism of Y4 causes
significant reduction in body weight and adiposity via effects
on metabolic rate and energy distribution [48].
We readily acknowledge the small number of simple steatosis
samples in the present study. This limitation was due to the lack
of availability of simple steatosis patients from our previous
study that comprised three major ethnic groups [49–50]. These
patients were recruited from the UMMC, a tertiary referral
center, which could explain the greater number of NASH
patients as compared to those with simple steatosis. In order to
minimise ethnicity as a potential confounding factor, we selected
samples taken from only one specific ethnic group, namely the
Malays, for both the NASH and the simple steatosis group.
Under these conditions, the number of simple steatosis patients
that we were able to obtain was only 10. Despite the limited
numbers of patients available, several of our findings were
statistically significant. Importantly, chromosome 11q11 which
was one of the most frequently deleted CNVs in our study, was
also frequently deleted from 10 hepatic steatosis patients from
the study by Royo et al. [51]. It should be noted that the Royo
et al. study did not include any NASH patients. This
notwithstanding, our pilot study was designed to provide an
initial screen of the structural genomic aberrations present in
NAFLD samples. Simple steatosis patients mostly presented with
either a copy number gain or a loss event at one locus, unlike
the NASH group which tended to exhibit both events. In
addition, a greater number of CNVs were identified in the
NASH group as compared to the simple steatosis group. This
could be explained by the complex pathogenesis of NAFLD
especially at the NASH stage, involving not only the ‘first hit’
mechanism but also the ‘second hit’ [4]. In this study, we were
mainly concerned with identifying CNVs that were common to
both simple steatosis and NASH, particularly when the CNV
frequency was higher in NASH than in simple steatosis (n=2),
as they could indicate involvement in the progression of the
disease. Surprisingly, histological data from the samples
harbouring these CNVs (12p13.2 and 11p15.4) showed a higher
frequency (53.3% and 71.4% respectively) of fibrosis score $2,
thereby supporting the disease progression model.
The ethical issue that precluded the use of liver biopsy for the
classification of controls (non-NAFLD) required us to adopt a
stringent definiton of controls in order to rule out fatty liver in the
control subjects; biochemical tests, ultrasonography and MRI
evaluations were therefore used to minimise misclassification of
our controls. To the best of our knowledge, this is the first study to
investigate a genome-wide profile of copy number variation in the
NAFLD spectrum; hence, determination of the CNV total
number, frequency, genomic location and gene content, is
challenging. The use of aCGH technology allows CNV discovery
at high resolution and hence allows confidence in CNV detection.
The use of 60mer probes provides high sensitivity and specificity to
accurately detect both known and de novo CNVs as compared to
shorter oligonucleotide probes [52]. The source of genes known to
be related to NAFLD was Malacard, which is known to use a text-
mining approach [53]. Hence, a manual verification of the gene
functions was performed that included only genes that have been
shown to be associated in either expression studies, genotyping or
protein array work. However, we cannot rule out the possibility
that other genes could be of importance in NAFLD, as more
comprehensive studies are still ongoing. Indeed, it was also difficult
for us to assess the significance of such CNVs given that multiple
genes often reside within the CNV intervals. We attempted to
overcome this limitation by performing a functional enrichment
analysis that covered all the genes residing within the CNV
regions.
Taken together, the results of our whole genome copy number
analysis have documented four rare and/or novel CNV loci that
are unique to NASH, and to the best of our knowledge, have not
previously been reported. This study nevertheless falls into the
hypothesis generating category rather than the hypothesis testing
category; hence, our results remain to be substantiated by
additional studies on larger patient groups. Moreover, additional
functional studies on the genes residing within these loci will be
needed to fully characterize the function of the genes and their
relationship, if any, to NASH.
Genome-Wide CNV Analysis and NAFLD
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